# Cholestasis Reversal: Efficacy of IV Fish Oil

> **NCT00910104** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mark Puder** · enrollment: 91 (actual)

## Conditions studied

- Parenteral Nutrition Associated Liver Disease
- Short Bowel Syndrome
- Gastrointestinal Disease

## Interventions

- **DRUG:** Omegaven®

## Key facts

- **NCT ID:** NCT00910104
- **Lead sponsor:** Mark Puder
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2019-01-23
- **Final completion:** 2019-01-23
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910104, "Cholestasis Reversal: Efficacy of IV Fish Oil". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00910104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*